Diagnosis: MS
New Drug Could Lead the Way

Reprinted from PN March 2003
View Forum | Print Article | Font Size + / - | Back

Promising results have emerged from a short-term Phase II multiple sclerosis (MS) clinical trial of Antegren? (natalizumab), a monoclonal antibody agent that appears to have a completely different mode of action to currently available MS treatments.

In the March 2003 PN/Paraplegia News, read about this new drug: how it works, results of the short-term clinical trial, possible side effects, and the future for Antegren and people with MS.


To read more about this, order the March 2003 PN, Click Here.
To Subscribe, Click Here.

Article Forum

PN Forum discussions are intended to provide a place for free-flowing exchange of information, opinions, and comments and are designed to provide an enjoyable and informative expression for all participants.
Please review our Forum Rules for complete details.

Login with username and password (Forgot Password?)
New Post

Diagnosis: MS
New Drug Could Lead the Way


Be the first to comment on this article.
(Register or login to add comments.)